Mark J. Foley - 29 Nov 2021 Form 4 Insider Report for Revance Therapeutics, Inc.

Role: CEO, Director
Signature: /s/ Gordon Ho, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 29 Nov 2021
Net transactions value: +$515,924
Form type: 4
Filing time: 29 Nov 2021, 20:24:09 UTC
Previous filing: 15 Oct 2021
Next filing: 05 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Purchase	$515,924	+40,000	+56%	$12.90	110,913	29 Nov 2021	See footnote	F1, F2
holding	RVNC	Common Stock						769,065	29 Nov 2021	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Table 1, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.76 to $13.0305. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2	These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.

Content

The price reported in Table 1, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.76 to $13.0305. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.